Correlation between down-expression of miR-431 and clinicopathological significance in HCC tissues

• L. Pan ^[1] ; F. Ren ^[1] ; M. Rong ^[1] ; Y. Dang ^[1] ; Y. Luo ^[1] ; D. Luo ^[1] ; G. Chen ^[1]
  1. [1] First Affiliated Hospital of GuangXi Medical University

     First Affiliated Hospital of GuangXi Medical University

     China

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 7 (July), 2015, págs. 557-563
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background and aims Researches have shown that miRNAs have been proposed as novel diagnostic biomarkers for classification and prognostic stratification of HCC. However, whether or not miR-431 contributes to the progression of HCC remains unknown. Therefore, we aimed to investigate the clinicopathological significance of miR-431 in HCC.

    Methods MiR-431 expression in 95 HCC cases and corresponding adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Furthermore, statistical analysis was performed to identify the correlations between expression of miR-431 and a variety of clinicopathological parameters and patient recurrence. The area under the receiver operating characteristic curve (AUC) was used to evaluate the accuracy of miR-431 as a biomarker for HCC diagnosis and prediction of disease deterioration.

    Results MiR-431 was markedly down-regulated in the HCC samples (1.1885 ± 0.75867) compared with corresponding adjacent tumor tissues (1.7957 ± 0.89333, P < 0.001). The AUC of low miR-431 expression to diagnose HCC was 0.668 (95 % CI 0.592–0.744, P < 0.001). MiR-431 down-expression was correlated with multiple malignant characteristics, including lymph node metastasis (r = −0.455, P < 0.001), clinical TNM stage (r = −0.223, P = 0.030), MTDH (r = −0.292, P = 0.006), vaso-invasion (r = −0.204, P = 0.047), MVD (r = −0.281, P = 0.006) and HCV (r = 0.215, P = 0.037). Additionally, the recurrent time of lower miR-431 expression group was 56.602 ± 3.914 months, much longer than that in the high expression group (50.009 ± 2.731 months), however, no significant difference was noted (χ 2 = 0.005, P = 0.943).

    Conclusions The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.